Literature DB >> 25749057

Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.

Camus Nimmo1, Marc Lipman2, Patrick P J Phillips3, Timothy McHugh4, Andrew Nunn3, Ibrahim Abubakar5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25749057     DOI： 10.1016/S1473-3099(14)70885-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  9 in total

Review 1.  New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.

Authors:  Santiago Caño-Muñiz; Richard Anthony; Stefan Niemann; Jan-Willem C Alffenaar
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

Review 2.  A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal:  J Clin Pharmacol       Date:  2017-07-24       Impact factor: 3.126

3.  Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials.

Authors:  Isabelle R Weir; Sean Wasserman
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

4.  Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

Authors:  Anushka Naidoo; Maxwell Chirehwa; Helen McIlleron; Kogieleum Naidoo; Sabiha Essack; Nonhlanhla Yende-Zuma; Eddy Kimba-Phongi; John Adamson; Katya Govender; Nesri Padayatchi; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.758

5.  Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Authors:  Neesha Rockwood; Jotam G Pasipanodya; Paolo Denti; Frederick Sirgel; Maia Lesosky; Tawanda Gumbo; Graeme Meintjes; Helen McIlleron; Robert J Wilkinson
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079

6.  Rethinking non-inferiority: a practical trial design for optimising treatment duration.

Authors:  Matteo Quartagno; A Sarah Walker; James R Carpenter; Patrick Pj Phillips; Mahesh Kb Parmar
Journal:  Clin Trials       Date:  2018-06-05       Impact factor: 2.486

Review 7.  Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.

Authors:  Patrick P J Phillips; Carole D Mitnick; James D Neaton; Payam Nahid; Christian Lienhardt; Andrew J Nunn
Journal:  PLoS Med       Date:  2019-03-22       Impact factor: 11.069

8.  In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.

Authors:  Elsje Pienaar; Véronique Dartois; Jennifer J Linderman; Denise E Kirschner
Journal:  BMC Syst Biol       Date:  2015-11-14

9.  Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Authors:  Patrick P J Phillips; Carl M Mendel; Divan A Burger; Angela M Crook; Angela Crook; Andrew J Nunn; Rodney Dawson; Andreas H Diacon; Stephen H Gillespie
Journal:  BMC Med       Date:  2016-02-04       Impact factor: 8.775
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.